Clinical Trials Sponsored by Suzhou SinoMed Biomaterials Co., Ltd

Total 614 results

Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)

DLBCL

China
Suzhou Genhouse Bio Co., Ltd.

Recruiting

Dose Finding Study of GH35 in Patients With Advanced Solid Tumors

AdvAdvanced Solid Tumors | Kirsten Rat Sarcoma

China
Suzhou Junjing BioSciences Co., Ltd.

Recruiting

AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer

Lung Cancer

China
Coherent Biopharma (Suzhou) Co., Ltd.

Recruiting

A Study of CBP-1018 in Patients With Advanced Solid Tumors

Solid Tumor

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Efficacy and Safety of SHR-1314 in Patients With Active Ankylosing Spondylitis

Ankylosing Spondylitis

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic Malignancy

Hematologic Malignancy

China
Coherent Biopharma (Suzhou) Co., Ltd.

Recruiting

A Study of CBP-1008 in Patients With Advanced Solid Tumor

Advanced Solid Tumor

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Intense Monitoring Study on Tyvyt

Relapsed or Refractory Classical Hodgkin's Lymphoma

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Terminated

Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

ALK-positive Non-small Cell Lung Cancer

China
Suzhou Abogen Biosciences Co., Ltd.

Active, not recruiting

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine

COVID-19

Philippines, Pakistan, United Arab Emirates, Indonesia
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Terminated

A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer

Triple Negative Breast Cancer

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal

Differentiated Thyroid Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase Inhibitor)

Gout Arthritis

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Active, not recruiting

A Study With Jaktinib Hydrochloride Cream Applied Topically to Subjects With Alopecia Areata (AA)

Alopecia Areata(AA)

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of IBI311 in Subjects With Active Thyroid Eye Disease

Thyroid Eye Disease

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Jaktinib in Healthy Volunteers

Healthy Volunteers

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Active, not recruiting

Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

ADME Study of [14C]-Jaktinib in Healthy Male Subjects

Healthy Adult Male Volunteers

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of [14C]IBI351 in Healthy Subjects

Healthy Subjects

China
Suzhou Transcenta Therapeutics Co., Ltd.

Completed

A Phase I Study of MSB2311 in Advanced Solid Tumors

Advanced Solid Tumors

United States
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise

Type 2 Diabetes

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis

Myelofibrosis

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Study of Jaktinib In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib Treatment.

Myelofibrosis

China
Advaccine (Suzhou) Biopharmaceuticals Co., Ltd.

Active, not recruiting

Safety and Efficacy of BARS13 in the Elderly

Respiratory Syncytial Virus Infections

Australia
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Phase Ia/Ib Study of IBI315 in Patients With HER2-expressing Advanced Solid Tumor

Advanced Solid Tumor

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of IBI351 in Healthy Subjects

Healthy Subjects

China
Innovent Biologics (Suzhou) Co. Ltd.

Suspended

Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Suzhou Transcenta Therapeutics Co., Ltd.

Terminated

Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Cancers | Metastatic Human Papillomavirus-Related Malignant Neoplasm

United States
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Active, not recruiting

The Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of IBI311 in Healthy Volunteers

Healthy

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers

Advanced Malignant Tumors Lymphomas

United States
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Phase I Study of IBI325 in Patients With Advanced Solid Tumor

Solid Tumor

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia

Homozygous Familial Hypercholesterolemia

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Terminated

A Study of Donafenib Monotherapy in Advanced Oesophageal Cancer

Oesophageal Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

A Study of IBI362 in Participants With Obesity or Overweight

Obesity Or Overweight

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI345

CLDN18.2 Positive Solid Tumors

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

Study of IBI318 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Advanced Cutaneous Squamous Cell Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma

Indolent Non-hodgkin Lymphoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)

Gastric Adenocarcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of Dose Escalation of IBI321 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant Tumors

Advanced Malignancies

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.

Advanced Solid Tumors

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC

Lung Neoplasms

China
Suzhou Abogen Biosciences Co., Ltd.

Active, not recruiting

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19 Omicron) mRNA Vaccine (Phase 1)

COVID-19

United Arab Emirates
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Terminated

Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML

Acute Myeloid Leukemia (AML)

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Safety and Efficacy of Topical Recombinant Human Thrombin(rhThrombin) for Surgical Hemostasis

Surgical Hemostasis

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors

Cancer, Solid Tumor

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

Study of the Efficacy and Safety of IBI319 in Patients With Advanced Malignant Tumors

Advanced Malignant Tumors

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

Efficacy and Safety of IBI310 Combined With Sintilimab in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China

3

Subscribe